June 18, 2018 - By Adrian Erickson

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo


APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ:AGTC) institutional sentiment increased to 0.59 in Q1 2018. Its up 0.04, from 0.55 in 2017Q4. The ratio is more positive, as 16 hedge funds increased or opened new positions, while 27 cut down and sold equity positions in APPLIED GENETIC TECHNOLOGIES CORP. The hedge funds in our partner’s database reported: 6.00 million shares, down from 6.64 million shares in 2017Q4. Also, the number of hedge funds holding APPLIED GENETIC TECHNOLOGIES CORP in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 10 Reduced: 17 Increased: 11 New Position: 5.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $80.59 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

The stock increased 3.49% or $0.15 during the last trading session, reaching $4.45. About 40,064 shares traded. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 15.14% since June 18, 2017 and is downtrending. It has underperformed by 27.71% the S&P500.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on September, 12. They expect $-0.23 earnings per share, down 27.78 % or $0.05 from last year’s $-0.18 per share. After $-0.45 actual earnings per share reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts -48.89 % EPS growth.

Dafna Capital Management Llc holds 0.79% of its portfolio in Applied Genetic Technologies Corporation for 421,000 shares. 683 Capital Management Llc owns 300,000 shares or 0.1% of their US portfolio. Moreover, Steinberg Global Asset Management has 0.1% invested in the company for 177,154 shares. The Connecticut-based Altrinsic Global Advisors Llc has invested 0.04% in the stock. Spark Investment Management Llc, a New York-based fund reported 84,700 shares.

More recent Applied Genetic Technologies Corporation (NASDAQ:AGTC) news were published by: which released: “45 Biggest Movers From Yesterday” on May 25, 2018. Also published the news titled: “AGTC Announces Expansion of Clinical and Regulatory Leadership Teams” on June 14, 2018.‘s news article titled: “32 Stocks Moving In Monday’s Mid-Day Session” with publication date: June 11, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: